Compare Agnico Eagle Mines Ltd (AEM) vs Amgen, Inc. (AMGN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agnico Eagle Mines Ltd vs Amgen, Inc. — how do they compare? Agnico Eagle Mines Ltd trades at $143.55 (market cap $75.10B), while Amgen, Inc. trades at $368.75 (market cap $198.67B). The key difference: Amgen, Inc. is far larger — about 2.6× Agnico Eagle Mines Ltd's market cap, and Amgen, Inc. pays the higher dividend (2.74%). Which is the better fit depends on your goals.
| AEM | AMGN | |
|---|---|---|
Market Cap | $75.10B | $198.67B |
Sector | Basic Materials | Health |
52-Week High | $252.19 | $388.16 |
52-Week Low | $116.14 | $271.18 |
Enterprise Value | $72.30B | $243.95B |
Dividend Yield | 1.2% | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agnico Eagle Mines (AEM) trades at $150.33, down 2.29% amid a bearish technical signal but maintains strong fundamentals with a 14.59 P/E ratio and 39.46% net margin. Recent quarterly earnings consistently beat estimates, including Q1 2026 EPS of $3.40 versus $3.19 expected. Revenue grew to $11.91B in 2025, while news highlights temporary mining suspension at Barnat pit but affirms long-term growth projects.
Outlook remains positive with a $222.40 analyst consensus target, though risks include operational disruptions and gold price volatility. The stock offers value with robust cash flow and 67.74% buy ratings, but investors should monitor execution of expansion plans amid bearish technical indicators.
Amgen (AMGN) trades at $368.10, down 1.62% on the day, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net income margin of 20.96% and has beaten earnings estimates for three consecutive quarters. Recent news includes a favorable court ruling blocking a price cap on Enbrel and analyst upgrades, though regulatory challenges for Tavneos in Europe pose headwinds. Cash flow from operations remains robust at nearly $10 billion annually.
The outlook for AMGN is positive with steady revenue growth and high margins, but investors face risks from patent expirations and regulatory scrutiny. Analyst consensus is bullish with a $358.25 price target, though the current price exceeds this, suggesting near-term consolidation may occur. The company's strong cash generation supports dividend payments, but high debt levels require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agnico Eagle Mines Ltd
Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.
Read more on AEM →About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →
